GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcutis Biotherapeutics Inc (NAS:ARQT) » Definitions » Operating Margin %

Arcutis Biotherapeutics (Arcutis Biotherapeutics) Operating Margin % : -452.23% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Arcutis Biotherapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Arcutis Biotherapeutics's Operating Income for the three months ended in Dec. 2023 was $-61.17 Mil. Arcutis Biotherapeutics's Revenue for the three months ended in Dec. 2023 was $13.53 Mil. Therefore, Arcutis Biotherapeutics's Operating Margin % for the quarter that ended in Dec. 2023 was -452.23%.

The historical rank and industry rank for Arcutis Biotherapeutics's Operating Margin % or its related term are showing as below:

ARQT' s Operating Margin % Range Over the Past 10 Years
Min: -8183.04   Med: -4293.77   Max: -404.49
Current: -404.49


ARQT's Operating Margin % is ranked worse than
61.63% of 1032 companies
in the Biotechnology industry
Industry Median: -168.78 vs ARQT: -404.49

Arcutis Biotherapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Arcutis Biotherapeutics's Operating Income for the three months ended in Dec. 2023 was $-61.17 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-241.10 Mil.


Arcutis Biotherapeutics Operating Margin % Historical Data

The historical data trend for Arcutis Biotherapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcutis Biotherapeutics Operating Margin % Chart

Arcutis Biotherapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial - - - -8,183.04 -404.49

Arcutis Biotherapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,310.84 -2,742.36 -1,286.38 -96.84 -452.23

Competitive Comparison of Arcutis Biotherapeutics's Operating Margin %

For the Biotechnology subindustry, Arcutis Biotherapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arcutis Biotherapeutics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcutis Biotherapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Arcutis Biotherapeutics's Operating Margin % falls into.



Arcutis Biotherapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Arcutis Biotherapeutics's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-241.101 / 59.606
=-404.49 %

Arcutis Biotherapeutics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-61.169 / 13.526
=-452.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arcutis Biotherapeutics  (NAS:ARQT) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Arcutis Biotherapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Arcutis Biotherapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Arcutis Biotherapeutics (Arcutis Biotherapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3027 Townsgate Road, Suite 300, Westlake Village, CA, USA, 91361
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Executives
Masaru Matsuda officer: SVP and General Counsel 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Frazier Life Sciences Viii, L.p. 10 percent owner 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Larry Todd Edwards officer: Chief Commercial Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Patrick Burnett officer: See Remarks C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Todd Franklin Watanabe director, officer: President and CEO C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
Howard G. Welgus director C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
Scott L Burrows officer: Chief Financial Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Patricia A. Turney officer: Senior VP, Manufacturing C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
David W Osborne officer: Chief Technical Officer
Kenneth A. Lock officer: Chief Commercial Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
Matthew Richard Moore officer: SVP and Chief Business Officer C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Neha Krishnamohan director 12707 HIGH BLUFF DRIVE, SAN DIEGO CA 92130
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Keith R Leonard director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Bhaskar Chaudhuri director ONE ENTERPRISE, ALISO VIEJO CA 92656